SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

Share Price is delayed by 15 minutes
Get Live Data
0.18    -0.022 (-10.89%)
Bid:
0.17
Ask:
0.19
Spread: 0.02 (11.765%)
Market Cap: £4.70m
NFX Live PriceLast checked at - London Stock Exchange

Intraday Nuformix Share Chart

Director/PDMR Shareholding

31 Jan 2022 14:09

RNS Number : 1883A
Nuformix PLC
31 January 2022
 

 

31 January 2022

Nuformix plc

 

("Nuformix" or the "the Company")

  

Director/PDMR Shareholding

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that it has granted a total of 3,000,000 warrants each to Dr Alastair Riddell, Dr Julian Gilbert and Maddy Kennedy with an exercise price of 1.45p per share.

 

- Ends -

 

 Enquiries:

Nuformix plc

via Walbrook

Dr Alastair Riddell, Executive Chairman

 

Allenby Capital Limited

 

+44 (0) 20 3328 5656

Nick Athanas / George Payne (Corporate Finance)

Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)

 

Walbrook PR

 

nuformix@walbrookpr.com or +44 (0)20 7933 8780

Anna Dunphy / Phillip Marriage

Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Dr Alastair Riddell

2

 

Reason for the notification

 

a)

 

Position/status

 

PDMR - Executive Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Nuformix plc

b)

 

LEI

 

2138003XG3H3I2J3BJ24

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Warrants to acquire ordinary shares at a price of 1.45p per share.

 

 

GB00BYW79Y38

b)

 

Nature of the transaction

 

Granting of warrants

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

0

 

3,000,000

 

d)

 

Aggregated information

Single Transaction

 

e)

 

Date of the transaction

 

31 January 2022

f)

 

Place of the transaction

 

Off-market transaction

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Dr Julian Gilbert

2

 

Reason for the notification

 

a)

 

Position/status

 

PDMR - Non-executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Nuformix plc

b)

 

LEI

 

2138003XG3H3I2J3BJ24

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Warrants to acquire ordinary shares at a price of 1.45p per share.

 

 

GB00BYW79Y38

b)

 

Nature of the transaction

 

Issue of warrants

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

0

 

3,000,000

 

d)

 

Aggregated information

Single Transaction

 

e)

 

Date of the transaction

 

31 January 2022

f)

 

Place of the transaction

 

Off-market transaction

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Maddy Kennedy

2

 

Reason for the notification

 

a)

 

Position/status

 

PDMR - Non-executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Nuformix plc

b)

 

LEI

 

2138003XG3H3I2J3BJ24

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Warrants to acquire ordinary shares at a price of 1.45p per share.

 

 

GB00BYW79Y38

b)

 

Nature of the transaction

 

Issue of Warrants

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

0

 

3,000,000

 

d)

 

Aggregated information

Single Transaction

 

e)

 

Date of the transaction

 

31 January 2022

f)

 

Place of the transaction

 

Off-market transaction

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHWPUMUGUPPGCG
Date   Source Headline
28th May 20267:00 amRNSHalf Year Report
31st Mar 20267:00 amRNSTotal Voting Rights
11th Mar 20267:00 amRNS£1.0 million Placing
10th Mar 20267:00 amRNSConfirmation of US ODD for NXP002 in IPF
3rd Mar 202610:05 amRNSResult of AGM
5th Feb 202612:00 pmRNSPosting of Annual Report and Notice of AGM
27th Jan 20267:00 amRNSAnnual Results for period ended 30 September 2025
28th Nov 20253:22 pmRNSTotal Voting Rights
12th Nov 20257:01 amRNSUpdate re. US FDA ODD Application
12th Nov 20257:00 amRNSResults of Underwritten Open Offer
28th Oct 20257:00 amRNSUnderwritten Open Offer
10th Oct 20257:00 amRNSChange of Auditor
25th Sep 20257:00 amRNS-REuropean Respiratory Society Congress Attendance
11th Aug 20257:00 amRNSUS FDA ODD Application Submitted for NXP002
30th May 20252:24 pmRNSTotal Voting Rights
29th May 20257:00 amRNSConfirmation of European ODD for NXP002
23rd May 20251:08 pmRNSPublication of a Prospectus
22nd May 20257:00 amRNS£210,000 Placing
19th May 20257:00 amRNS-RAttendance at American Thoracic Society Congress
2nd May 20257:00 amRNSHalf-year Report
30th Apr 20257:00 amRNSConfirmation of European Orphan Drug Designation
29th Apr 20257:00 amRNSChange of Registered Office and Company Secretary
14th Apr 20257:00 amRNSExercise of Warrants
9th Apr 20257:00 amRNSNXP002 Update
20th Mar 202511:10 amRNSResult of AGM
28th Feb 202512:30 pmRNSTotal Voting Rights
14th Feb 20252:18 pmRNSPosting of Annual Report and Notice of AGM
30th Jan 20257:00 amRNS£168,750 Placing
29th Jan 20257:00 amRNSAnnual Results for period ended 30 September 2024
28th Jan 20257:00 amRNSNXP002 ODD Application Submitted
13th Jan 20257:00 amRNSNXP002 Orphan Drug Designation Draft Application
29th Nov 20245:00 pmRNSTotal Voting Rights
5th Nov 20242:25 pmRNSDirector/PDMR Dealings
4th Nov 202410:17 amRNSResult of General Meeting
16th Oct 20241:37 pmRNSPublication of Prospectus & Notice of GM
20th Sep 20242:24 pmRNS£300,000 Fundraise
18th Jun 20247:00 amRNSHalf-year Report
17th Jun 20247:00 amRNSPatent Update
19th Mar 20242:39 pmRNSResult of AGM
1st Mar 20247:00 amRNSSubscription to raise £150,000
15th Jan 202411:30 amRNSPosting of Annual Report and Notice of AGM
3rd Jan 20247:00 amRNSResults for the period ended 30 September 2023
18th Dec 20237:00 amRNSNXP001 Update
23rd Oct 20237:00 amRNSNotice of Allowance of NXP002 Patent in Japan
18th Sep 20237:00 amRNSNXP001 Update
24th Aug 20231:22 pmRNSResult of Annual General Meeting
31st Jul 20232:00 pmRNSNotice of AGM
26th Jul 20232:55 pmRNSHolding(s) in Company
2nd Jun 20237:00 amRNSInvestor Online Q&A
25th May 20237:00 amRNSChange of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.